Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–93.

Article  CAS  PubMed  Google Scholar 

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386:1397–408.

Article  CAS  PubMed  Google Scholar 

Arbel R, Sagy YW, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med. 2022;387:790–8.

Article  CAS  PubMed  Google Scholar 

Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clin Infect Dis. 2022;76:1158–9.

Google Scholar 

V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–70.

Article  PubMed  Google Scholar 

Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S-H. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J Med Chem. 2016;59:6595–628.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–93.

Article  CAS  PubMed  Google Scholar 

Fumagalli V, Lucia PD, Ravà M, Marotta D, Bono E, Grassi S et al. Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses. Embo Mol Med. 2023. https://doi.org/10.15252/emmm.202317580.

Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG. Early Programming of T Cell Populations Responding to Bacterial Infection. J Immunol. 2000;165:6833–9.

Article  CAS  PubMed  Google Scholar 

Corbin GA, Harty JT. Duration of Infection and Antigen Display Have Minimal Influence on the Kinetics of the CD4+ T Cell Response to Listeria monocytogenes Infection. J Immunol. 2004;173:5679–87.

Article  CAS  PubMed  Google Scholar 

Badovinac VP, Porter BB, Harty JT. CD8+ T cell contraction is controlled by early inflammation. Nat Immunol. 2004;5:809–17.

Article  CAS  PubMed  Google Scholar 

Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F et al. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. Jci Insight 2022; 7. https://doi.org/10.1172/jci.insight.163471.

Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifirò G. Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Front Pharm. 2020;11:588654.

Article  CAS  Google Scholar 

Thompson J, Wang Y, Dreischulte T, Barreiro O, Gonzalez RJ, Hanč P et al. Association between Bisphosphonate use and COVID-19 related outcomes. eLife 2023; 12. https://doi.org/10.7554/elife.79548.

Favus MJ. Bisphosphonates for Osteoporosis. N Engl J Med. 2010;363:2027–35.

Article  CAS  PubMed  Google Scholar 

Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:2062–81

Article  PubMed  Google Scholar 

Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.

Article  CAS  PubMed  Google Scholar 

Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages. Curr Pharm Des. 2010;16:2950–60.

Article  CAS  PubMed  Google Scholar 

Brufsky A, Marti JLG, Nasrazadani A, Lotze MT. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med. 2020;18:261.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poccia F, Agrati C, Castilletti C, Bordi L, Gioia C, Horejsh D, et al. Anti–Severe Acute Respiratory Syndrome Coronavirus Immune Responses: The Role Played by Vγ9Vδ2 T Cells. J Infect Dis. 2006;193:1244–9.

Article  CAS  PubMed  Google Scholar 

Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139:101–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tu W, Zheng J, Liu Y, Sia SF, Liu M, Qin G, et al. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized miceHuman γδ T cells control influenza infection. J Exp Med. 2011;208:1511–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Favot CL, Forster C, Glogauer M. The effect of bisphosphonate therapy on neutrophil function: a potential biomarker. Int J Oral Max Surg. 2013;42:619–26.

Article  CAS  Google Scholar 

Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Min Res. 2010;25:606–16.

Article  CAS  Google Scholar 

Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med. 2011;9:177.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica. 2006;91:1165–71.

CAS  PubMed  Google Scholar 

Xia Y, Xie Y, Yu Z, Xiao H, Jiang G, Zhou X, et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell. 2018;175:1059–73.

Article  CAS  PubMed  Google Scholar 

Tonti E, Jiménez de Oya N, Galliverti G, Moseman EA, Di Lucia P, Amabile A, et al. Bisphosphonates Target B Cells to Enhance Humoral Immune Responses. Cell Rep. 2013;5:323–30.

Article  CAS  PubMed  Google Scholar 

Lee P, Ng C, Slattery A, Nair P, Eisman JA, Center JR. Preadmission Bisphosphonate and Mortality in Critically Ill Patients. J Clin Endocrinol Metab. 2016;101:1945–53.

Article  CAS  PubMed  Google Scholar 

Sing C, Kiel DP, Hubbard RB, Lau WC, Li GH, Kung AW, et al. Nitrogen‐Containing Bisphosphonates Are Associated With Reduced Risk of Pneumonia in Patients With Hip Fracture. J Bone Min Res. 2020;35:1676–84.

Article  CAS  Google Scholar 

Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology. 2014;53:19–31.

Article  CAS  PubMed  Google Scholar 

Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C. Zoledronic acid for the treatment of osteopenia in pediatric Crohn’s disease. Pediatr Int. 2010;52:754–61.

Article  CAS  PubMed  Google Scholar 

George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. J Clin Endocrinol Metab. 2015;100:4163–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, et al. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. J Virol. 2021;95:e00014–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim PS, Dimcheff DE, Siler A, Schildhouse RJ, Chensue SW. Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response. Clin Immunol. 2022;236:108959.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benschop RJ, Tuttle JL, Zhang L, Poorbaugh J, Kallewaard NL, Vaillancourt P, et al. The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination. Sci Transl Med. 2022;14:eabn3041.

Article  CAS  PubMed  Google Scholar 

Schultz-Cherry S, McGargill MA, Thomas PG, Estepp JH, Gaur AH, Allen EK, et al. Cross-reactive antibody response to mRNA SARS-CoV-2 vaccine after recent COVID-19-specific monoclonal antibody therapy. Open Forum Infect Dis. 2021;8:ofab420.

Article  PubMed  PubMed Central  Google Scholar 

Rotundo S, Vecchio E, Abatino A, Giordano C, Mancuso S, Tassone MT, et al. Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2. Int J Infect Dis. 2022;124:55–64.

Article  CAS  PubMed  PubMed Central  Google Scholar